한국의 신약 허가기간에 대한 조사 연구(2011~2017년) = Study on New Drug Application Timeline in Korea between 2011 and 2017

다국어 초록 (Multilingual Abstract)

In many countries, there is a growing interest in the new drug approval timeline as well as drug lag for new drug approval. We examine the actual timeline required for the approval and NDA (New Drug Application) review timeline, analyzed the relevant influencing factors in Korea, also compared drug lag with that in the US and Europe. This study was conducted on approved new drugs in Korea from 2011 to 2017 by KRPIA (Korea Research-based Pharmaceutical Industry Association) members. The data set included drug name, active ingredients, company name, orphan drug status, therapeutic class, application date, approval date etc. NDA review period represented the difference between the date of submission and the date of approval by the MFDS (Ministry of Food and Drug Safety). Relative submission gap was measured by the difference between the earliest submission date in FDA (Food and Drug Administration) or EMA (European Medicines Agency) and submission date in MFDS, and approval gap was calculated from the earliest approval date in FDA or EMA to approval date in MFDS. Regression analyze was used to identify the factors associated with NDA timeline. In total 115 approved new drugs in Korea, the average NDA timeline was 299.7days (median=293 days), and delayed by 15.3days (p=0.0250) on average over time. The study contained 73 chemicals (63.5%) and 42 biologicals (36.5%). In the case of orphan drugs, the NDA timeline was 187.1days faster than general new drugs on average (p<0.0001). There was a difference by TA (Therapeutic Anatomy), but it wasn’t statistically significant.

목차 (Table of Contents)

• 서 론(Introduction) 연구 방법(Research Methods) 결 과(Results) 고 찰(Discussion) 결 론(Conclusion) 감사의 말씀(Acknowledgment) Conflict of Interest References

참고문헌 (Reference)

1 "https://www.whocc.no/atc_ddd_index/"

2 Naci, H., "Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval" 95 : 261-, 2017

3 Andersson, F., "The drug lag issue : The debate seen from an international perspective" 22 : 53-, 1992

4 Chung, C. J., "Study on Drug Innovation Lag in Taiwan" 14 : 1-, 2006

5 Ueno, T., "Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan" 95 : 533-, 2014

6 Nishiyama, K., "Relationship Between the Review Time and Various PMDA Consultations in Recent New Drug Approval Cases in Japan" 52 : 731-, 2018

7 Downing, N. S., "Regulatory review of novel therapeutics-comparison of three regulatory agencies" 366 : 2284-, 2012

8 Downing, N. S., "Regulatory Review of New Therapeutic Agents-FDA versus EMA, 2011-2015" 376 : 1386-, 2017

9 Lee, S. W., "Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017" 2017

10 Centre for Innovation in Regulatory Science, "New drug approvals in six major authorities 2008-2017: Focus on the availability of medicines and company size"

11 Kikuchi, C., "Influence of Drug Lag on New Drug Label Revisions" 53 : 138-, 2019

12 Organisation for Economic C-operation and Development, "Health-care Reform in Japan: Controlling Costs, Improving Quality and Ensuring Equity"

13 "Economic survey of Japan 2009: Health care reform in Japan:controlleing costs, improving quality" OECD 2009

14 Kim, Y. J., "Comparison of Drug Lag between Korea and Japan using Public Data of Regulatory Authorities" Sungkyunkwan University 2015

15 Poirier, A. F., "Closing the Drug Lag for New Drug Submission and Review in Japan, An Industry Perspective" 98 : 486-, 2015

16 Tsuji, K., "Approval of new drugs 1999-2007 : comparison of the US, the EU and Japan situations" 35 : 289-, 2010

17 Kashoki, M., "A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016:Concordance, Discordance, and Why" 107 : 195-, 2020